Rotavirus vaccines
AssigneeCureVac AG
InventorsSusanne RAUCH, Benjamin PETSCH
Life of this patent
Estimating the term…
Abstract
The present invention provides mRNA sequences comprising at least one coding region, encoding for at least one epitope of a protein, or of a fragment, variant or derivative thereof, of a virus of the genus rotavirus. Particularly preferred is the protein respectively the protein cleavage product VP8* of rotavirus. The mRNA sequence may be used as a vaccine or generally as a pharmaceutical composition for prophylaxis or treatment of rotavirus infections.
Claims21
1-78. (canceled)
A method for stimulating an anti-rotavirus response in a mammalian patient comprising administering to the mammalian patient an effective amount of a pharmaceutical composition comprising RNA molecules formulated in a pharmaceutical carrier, said RNA molecules comprising at least one region encoding a rotavirus VP4 antigen comprising at least 100 amino acids of a VP8* cleavage product, wherein the RNA molecules comprise a 5′ Cap and a Poly(A) sequence of 60 to 250 consecutive adenosines, wherein the composition is administered by injection.
A pharmaceutical composition comprising purified RNA molecules formulated in a pharmaceutically acceptable carrier, said purified RNA molecules encoding a rotavirus VP4 antigen comprising at least 100 amino acids of a VP8* cleavage product, wherein the RNA molecules comprise a 5′ Cap and a Poly(A) sequence of 60 to 250 consecutive adenosines.
A method of making a pharmaceutical composition comprising:
- (i) obtaining purified RNA molecules encoding a rotavirus VP4 antigen comprising at least 100 amino acids of a VP8* cleavage product, wherein the RNA molecules comprise a 5′ Cap and a Poly(A) sequence of 60 to 250 consecutive adenosines;
- and
- (ii) formulating the purified RNA molecules in a pharmaceutically acceptable carrier, thereby producing a pharmaceutical composition.
Dependencies are inferred from the claim text.